Amygdala -Vergrößerung im Zusammenhang mit dem zukünftigen Beginn der Depression | Die Ergebnisse zeigten, dass Konverter tendenziell ein höheres Graustreifen in der Amygdala -Region des Gehirns im Vergleich zu Patienten mit Depression und gesunden Personen aufwiesen.

From the article: A neuroimaging study in Germany found that individuals who are about to develop depression tend to have higher gray matter volume of the amygdala brain region compared to both healthy individuals (not about to develop depression) and individuals already suffering from major depressive disorder. The research was [published](https://doi.org/10.1038/s41386-025-02075-6) in Neuropsychopharmacology.

Depression, also known as major depressive disorder, is a mental health condition marked by persistent low mood, loss of interest or pleasure, and a range of emotional and physical symptoms. It affects how a person feels, thinks, and handles daily activities such as sleeping, eating, and working. To be diagnosed, symptoms must last at least two weeks and interfere with daily functioning.

Common symptoms include fatigue, difficulty concentrating, feelings of worthlessness or guilt, sleep disturbances, changes in appetite, and suicidal thoughts. Depression can range from mild to severe and may occur once or repeatedly over a lifetime. Brain changes involving neurotransmitters like serotonin and norepinephrine are often involved. Stress, trauma, chronic illness, or major life changes can also trigger depressive episodes.

Study author Anna Kraus and her colleagues wanted to explore whether individuals about to develop depression for the first time (referred to as converters) have some specificities in the brain structure that would allow the prediction of this condition in advance. They note that previous studies report lower gray matter volume in the brains of individuals with depression, but this was related to the number of recurrent depressive episodes and the duration of illness.

Study participants came from two large independent longitudinal studies – the Marburg-Münster Affective Disorders Cohort Study (MACS) and the Münster Neuroimaging Cohort (MNC). Both are ongoing neuroimaging studies including converters, patients with affective, psychotic, and anxious disorders and healthy individuals used as controls.

Analysis for this study included 1279 participants from MACS and 430 from the MNC. In the MACS dataset there were 30 converters, 590 patients with depression, and 659 healthy participants. The MNC sample contained 15 converters, 158 patients with depression, and 257 healthy individuals. All participants underwent neuroimaging.